Background
==========

It is universally accepted that high serum concentrations of low-density lipoprotein cholesterol (LDL-C) can lead to atherosclerosis and accelerate the progression of atherosclerosis which is main causes of coronary artery disease \[[@B1]\]. Disruption of coronary atherosclerotic plaque (CAP) with subsequent thrombus formation may lead to sudden cardiac death, acute myocardial infarction, or unstable angina \[[@B2]\]. The evidence showed that reducing LDL-C can prevent coronary heart disease (CHD) and improve survival of CHD based on results from multiple randomized controlled trials (RCTs) \[[@B3],[@B4]\].

For many years coronary angiography (CAG) has been the gold standard method for the investigation of the anatomy of coronary arteries and measure the efficacy of anti-atherosclerotic drug therapies \[[@B5],[@B6]\]. But changes in CAG are measured only in the vascular lumen and not in the vessel wall \[[@B7]\], where the atherosclerotic process is located. Intravascular ultrasound (IVUS) is superior to angiography in the detection of early plaque formation and changes in plaque volume \[[@B8]-[@B10]\]. Through IVUS, Takagi et al. found that pravastatin lowered serum cholesterol levels and reduced the progression of CAP in patients with elevated serum cholesterol levels in 1997 \[[@B11]\]. Since then, multiple RCTs and no RCT about the effect of lowering LDL-C therapy on the regression of coronary atherosclerosis have been performed \[[@B12]-[@B16]\]. But the results varied with the RCTs: intensive LDL-C lowering therapy could reduce the progression of the plaques \[[@B12]\]; the mild LDL-C lowering did not \[[@B14]-[@B16]\]. The meta-analysis by Bedi et al. \[[@B17]\] evaluated the effects of LDL-C lowering on CAP by comparing statins with control therapy, and demonstrated that treatment with statins could slow atherosclerotic plaque progression and lead to plaque regression. The meta-analysis by Tian et al. \[[@B18]\] showed that CAP could be regressed in group of patients with \<100 mg of LDL-C level at follow up. But so far, there are no systematic reviews of the effects of LDL-C levels on CAP, and the targets of LDL-C level that could result in the regression of the plaques have not been settled.

In this study, we conducted meta-analyses to summarize findings from the current trials on LDL-C lowering therapy retarding the progression of the CAP and to identify the targets of LDL-C resulting in the regression of the CAP for guiding the LDL-C lowering therapy. Effect of different statins on the progression of the CAP was also investigated.

Methods
=======

Search strategy and selection criteria
--------------------------------------

An electronic literature search was performed to identify all relevant studies published in PubMed, EMBASE, and Cochrane databases in the English language from Jan. 1, 2000 to Jan. 1, 2014, using the terms "atherosclerosis" and "cholesterol blood level". The references of the studies were also searched for relevant studies. Studies were included using the following criteria: 1) randomized controlled or prospective, blinded end-points trials in which patients with CHD were assigned to LDL-C lowering therapy or placebo, and its primary end point was CAP change detected by IVUS; 2) report of LDL-C levels at baseline and follow-up (in each arm) or the level of LDL-C which can be calculated from the data in the paper (as in the trial by Yokoyama M \[[@B15]\], in which the LDL-C concentrations in control arm were directly extracted from the figure); 3) data on the volume of CAP, detected in IVUS at baseline and follow-up (in each arm), and volume of CAP was calculated as vessel volume minus lumen volume; Exclusion criteria were: 1) only CAP area or volume index or percent atheroma volume were detected by IVUS; 2) the levels of LDL-C at baseline or follow-up were not provided; and 3) target plaques were unstable.

Data extraction and quality assessment
--------------------------------------

Two investigators independently reviewed all potentially eligible studies and collected data on patient and study characteristics (author, year, design, sample size, the measures of LDL-C lowering, LDL-C levels, follow-up duration, and plaque volume), and any disagreement was resolved by consensus. The primary end point of this study was progression or regression of CAP detected by IVUS. Quality assessments were evaluated with Jadad quality scale \[[@B19]\].

Data synthesis and analysis
---------------------------

Continuous variables (change of CAP volume from baseline to follow-up) were analyzed using standardized mean differences (SMD).

The trials may have control arm and multiple active treatment arms, changes of plaque volume in every arms were used for pooled analysis. According to the levels and the reducing percentage of LDL-C at follow-up, the arms were grouped to following groups: ≤70, \>70 ≤ 100HP (\>70 ≤ 100 mg and reducing percentage ≥30%), \>70 ≤ 100MP (\>70 ≤ 100 mg and reducing percentage ≥0 \< 30%), \>70 ≤ 100LP (\>70 ≤ 100 mg and reducing percentage \<0%), \>100 mg/dL; and \<0, ≥0 \< 30, ≥30 \< 40, ≥40 \< 50, ≥50% respectively, to investigate the effect of different levels of LDL-C at follow up on CAPs. According to different statins, the arms were grouped to following groups: rosuvastatin, atorvastatin , pitavastatin, simvastatin, fluvastatin and pravastatin group, to investigate the effect of different statins on CAPs. The volume of CAP at follow up was compared with that at baseline to evaluate effect of LDL-C levels on regression of CAP.

Heterogeneity across trials (arms) was assessed via a standard χ^*2*^ test with significance being set at *p* \< 0.10 and also assessed by means of *I*^*2*^ statistic with significance being set at *I*^*2*^ \> 50%. Pooled analyses were calculated using fixed-effect models, whereas random-effect models were applied in case of significant heterogeneity across studies (arms). Sensitivity analyses (exclusion of one study at one time) were performed to determine the stability of the overall effects of LDL-C levels. Additionally, publication bias was assessed using the Egger regression asymmetry test. Mean LDL-C level and follow up duration of groups were calculated by descriptive statistics. A two-sided *p* values \< 0.05 was considered statistically significant. Statistical analyses were performed using STATA software 12.0 (StataCorp, College Station, Texas) and Review Manager V5.2 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012).

Results
=======

Eligible studies
----------------

The flow of selecting studies for the meta-analysis is shown in Figure [1](#F1){ref-type="fig"}. Briefly, of the initial 647 articles, one hundred and twenty of abstracts were reviewed, resulting in exclusion of 100 articles, and 20 articles were reviewed in full text, resulting in exclusion of 10 trials and inclusion of 18 additional trials. Twenty two RCTs \[[@B12]-[@B16],[@B20]-[@B31]\], \[[@B32]-[@B36]\] and six blinded end-points trial \[[@B37]-[@B42]\] were carefully evaluated. Five trials were excluded because of specific the index of plaque (volume index in TRUTH \[[@B24]\], trial by Kovarnik T \[[@B31]\], by Hattori K \[[@B42]\], and by Petronio AS \[[@B32]\]; area in LACMART \[[@B38]\]); GAIN \[[@B20]\] excluded because of no data of plaque volume at follow up; trial by Zhang X \[[@B25]\] excluded because of no data of LDL-C; trial by Hong YJ \[[@B30]\] excluded because of wrong data at follow up. Sixteen RCT (ESTABLISH \[[@B14]\], REVERSAL \[[@B13]\], A-PLUS \[[@B21]\], ACTIVATE \[[@B22]\], ILLUSTRATE \[[@B23]\], JAPAN-ACS \[[@B12]\], REACH \[[@B26]\], SATURN \[[@B28]\], ARTMAP \[[@B29]\], ERASE \[[@B34]\], STRADIVARIUS \[[@B35]\], PERISCOPE \[[@B36]\], and trials by Yokoyama M \[[@B15]\], by Kawasaki M \[[@B16]\], by Hong MK \[[@B27]\], and Tani S \[[@B33]\]) and four blinded end-points trial (ASTEROID \[[@B37]\], COSMOS \[[@B40]\], trial by Jensen LO \[[@B39]\] and trial by Nasu K \[[@B41]\]) were finally analyzed.

![Flow diagram of study-screening process.](1471-2261-14-60-1){#F1}

The characteristics of the included trials were shown in Table [1](#T1){ref-type="table"}. Among the 20 trials, there were 15 trials assessing statins (statin vs. usual care in 6 trials \[[@B14]-[@B16],[@B26],[@B33],[@B41]\]; intensive statin vs. moderate statin treatment in 5 trials \[[@B12],[@B13],[@B27]-[@B29]\]; follow up vs baseline in 3 trial \[[@B37],[@B39],[@B40]\], before acute coronary syndrome (ACS) vs after ACS in one trial \[[@B34]\]), 2 trials assessing enzyme acyl--coenzyme A: cholesterol acyltransferase (ACAT) inhibition (vs. placebo, both on the basis of mean LDL-C \< 102 after background lipid-lowering therapy with statins in 62-79% of patients) \[[@B21],[@B22]\], one trial assessing cholesteryl ester transfer protein (CETP) inhibitor torcetrapib (vs. statins on the basis of LDL-C ≤ 100 by statins) \[[@B23]\], one trial assessing a decreasing obesity drug: rimonabant (vs. placebo, on the basis of statins therapy) \[[@B35]\], and one trial assessing glucose-lowering agents (pioglitazone vs glimepiride on the basis of statins therapy) \[[@B36]\]. In three trials \[[@B12],[@B14],[@B34]\] with acute coronary syndrome, all target plaques were selected in non-culprit vessels. Overall, 5910 patients with CHD underwent serial IVUS examination for evaluating regression of CAP. Follow-up periods ranged from 2 to 24 months. The levels of LDL-C of each arm at baseline and follow-up were shown in Table [2](#T2){ref-type="table"}.

###### 

Features of participating trials

       **Authors and trial name**                                                     **Trial type and location**                                                                                                                  **Objective**                                                                    **Year**      **N T/C**      **Study population**   **LDL-C at follow up**   **LDL-C reducing percentage**                        **Treatments**                         **Follow up**                                                                                         **Main Results or Conclusion**
  ------------------------------------ -------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ ---------- ----------------- ---------------------- ------------------------ ------------------------------- ----------------------------------------------------------- --------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
     Okazaki S \[[@B14]\];ESTABLISH                               RCT: prospective, open-label, randomized, single center study. Japan                                                                            Effects of statins on changes in plaque by IVUS                                                     2004          24/24                ACS                    70/119                    -44/-0.004                                  Ato 20 vs Diet                               6                                                                  Plaque volume was sigificantly reduced in the Ato group compared with the control group.
     Nissen SE \[[@B13]\]; REVERSAL                               RCT: Double-blind, randomized active control multicenter trial; USA                                                                 Effects of statins (intensive or moderate) on changes in plaque by IVUS                                         2004         253/249               CAD                    79/110                      -46/-25                                   Ato 80 vs Pra40                             18         Ato reduced progression of coronary plaque compared with Pra. Compared with baseline values, Ato had no change in atheroma burden, whereas patients treated with Pra showed progression of coronary plaque.
      Tardif JC \[[@B21]\]; A-PLUS                  RCT: international, multicenter, double-blind, placebo-controlled, randomized trial. Canada, USA                                                   Effects of different dosage of avasimibe on changes in plaque by IVUS                                          2004     108/98/ 117/109           CAD               100/102/ 101/91             7.8/9.1/ 10.9/1.7         Ava50, 250, and 750 vs Placebo on the basis of LDL-C\<125        18                                                                       Avasimibe did not favorably alter coronary atherosclerosis as assessed by IVUS.
          Jensen LO \[[@B39]\]                               Open non placebo controlled serial investigation; blinded end-points. Denmark                                        To investigate the effect of lipid lowering by simvastatin on coronary atherosclerotic plaque volumes and lumen.                    2004           40                  CAD                      85                         -46.3                                        Sim 40                                  15                                                          Lipid-lowering therapy with Sim is associated with a significant plaque regression in coronary arteries.
         Yokoyama M \[[@B15]\]                                                   RCT: randomized, single center. Japan                                                                                            Effects of statins on changes in plaque by IVUS                                                     2005          29/30           Stable angina               87/124                    -35/-0.075                                  Ato 10 vs Diet                               6                                                                                 Treatment with Ato may reduce volumes of coronary plaques.
         Kawasaki M \[[@B16]\]                                         RCT: randomization, open-label, single-center study. Japan                                                                                 Effects of statins on changes in plaque by IVUS                                                     2005        17/18/17          Stable angina             95/102/149                 -39/-32/-0.02                            Ato 20, Pra 20 vs Diet                           6                                                                    Treatment with Ato and Pra may not significantly reduce volumes of coronary plaques.
           Tani S \[[@B33]\]                                        RCT: a prospective, single-center, randomized, open trial. Japan                                                    Investigated the effects of pravastatin on the serum levels of MDA-LDL and coronary atherosclerosis.                          2005          52/23           Stable angina              104/120                     -20/-2.4                                  Pra 10-20 vs con                              6                                                                  Plaque volume was sigificantly reduced in the Pra group compared with the control group.
     Nissen SE \[[@B22]\]; ACTIVATE                                                RCT: randomized, multicenter. USA                                                                                             Effects of pactimibe on changes in plaque by IVUS                                                    2006         206/202               CAD                    91/86                     -9.6/-14.9                                 Pac100 vs Placebo                            18                                                                Pac is not an effective strategy for limiting atherosclerosis and may promote atherogenesis.
     Nissen SE \[[@B37]\]; ASTEROID                             Prospective, open-label blinded end-points. USA, Germany, France, Canada                                                           Effects of Statins with different levels of LDL-C on changes in plaque by IVUS                                     2006           349                 CAD                      61                         -53.2                                        Ros 40                                  24                                                                         Therapy using Ros can result in significant regression of atherosclerosis.
       Yamada T \[[@B26]\]; REACH                                       RCT: open-labeled, randomized, multicenter study. Japan                                                       Evaluate the effect of marked reduction of LDL-C in patients with CHD on progression of atherosclerosis.                        2007          26/32           Stable angina               83/115                       -43/0                                     Ato 5 vs Con                               12                                                Ato treatment prevented the further progression of atherosclerosis by maintaining LDL-C below 100 mg/dl in patients with CHD.
    Nissen SE \[[@B23]\]; ILLUSTRATE                RCT: prospective, randomized, multicenter, double-blind clinical trial. North America or Europe                                                            Effects of CETP inhibitor on changes in plaque by IVUS                                                 2007         446/464               CAD                    87/70                      6.6/-13.3              Ato10-80 vs Ato+Tor 60 on the basis of LDL-C≤100 by Ato         24                          The Tor was associated with a substantial increase in HDL-C and decrease in LDL--C, and there was no significant decrease in the progression of coronary atherosclerosis.
    Nissen SE \[[@B36]\]; PERISCOPE                           RCT: prospective, randomized, multicenter, double-blind clinical trial. USA                          To compare the effects of pioglitazone, and glimepiride on the progression of coronary atherosclerosis in patients with type 2 diabete and CAD     2008         181/179             CAD, DM                96.1/95.6                     1.8/2.2                Gli1-4 mg vs Pio 15-45 mg on bases of statins therapy          18                              In patients with type 2 diabetes and CAD, treatment with Pio resulted in a significantly lower rate of progression of coronary atherosclerosis compared with Gli.
   Nissen SE \[[@B35]\]; STRADIVARIUS   RCT: Randomized, double-blinded, placebo-controlled, 2-group, parallel-group trial. North America, Europe, and Australia                     The effect of rimonabant on regression of coronary disease in patients with the metabolic syndrome and CAD                       2008         335/341           CAD,Obesity              87.6/86.3                    -4.7/-3.6                 Rim 20 mg vs Placebo on bases of statins therapy             18                                                           Rim can reduce progression of coronary plaque, and increase HDL-C levels, decrease triglyceride levels.
      Hiro T \[[@B12]\]; JAPAN-ACS                            RCT: prospective, randomized, open-label, parallel group, multicenter. Japan                                                                        Effects of statins on changes in plaque by IVUS                                                     2009         127/125               ACS                    84/81                       -36/-36                                   Ato 20 vs Pit 4                             10                                              The administration of Pit or Ato in patients with ACS equivalently resulted in significant regression of coronary plaque volume.
     Takayama T; COSMOS \[[@B40]\]                                Prospective, open-label blinded end-points multicenter trial. Japan                                 Evaluate the effect of rosuvastatin on plaque volume in patients with stable CAD, including those receiving prior lipid-lowering therapy        2009           126            Stable angina                 83                         -38.6                                       Ros \<20                                 14                                                             Ros exerted significant regression of coronary plaque volume in Japanese patients with stable CAD.
     Rodés-Cabau; ERASE \[[@B34]\]                                       RCT: multicenter randomized placebo-controlled. Canada                                                    Evaluate the early effects of newly initiated statin therapy on coronary atherosclerosis as evaluated by IVUS.                     2009          38/36                ACS                    77/63                       8.5/-37                               Before ACS vs After ACS                         \<2                                                              Newly initiated statin therapy is associated with rapid regression of coronary atherosclerosis.
           Nasu K \[[@B41]\]                      Prospective and multicenter study with nonrandomized and non-blinded design, but blinded end. Japan               Evaluate the effect of treatment with statins on the progression of coronary atherosclerotic plaques of a nonculprit vessel by serial IVUS.       2009          40/39           Stable angina              98.1/121                   -32.3/-1.1                                   Flu 60 vs Con                              12                                                                   One-year lipid-lowering therapy by Flu showed significant regression of plaque volume.
           Hong MK \[[@B27]\]                                                    RCT: randomized control trial. Korea.                                                                           Evaluated the effects of statin treatments for each component of coronary plaques.                                   2009          50/50           Stable angina               78/64                     -34.5/-44.8                                Sim 20 vs Ros 10                             12                                                        Statin treatments might be associated with significant changes in necrotic core and fibrofatty plaque volume.
     Nicholls SJ; SATURN \[[@B28]\]                          RCT: a prospective, randomized, multicenter, double-blind clinical trial. USA                                           Compare the effect of these two intensive statin regimens on the progression of coronary atherosclerosis.                        2011         519/520               CHD                  70.2/62.6                   -41.5/-47.8                                Ato 80 vs Ros 40                             24                                                                Maximal doses of Ros and Ato resulted in significant regression of coronary atherosclerosis.
       Lee CW \[[@B29]\]; ARTMAP                           RCT: a prospective, single-center, open-label, randomized comparison trial. Korea.                                  Compared the effects of atorvastatin 20 mg/day versus rosuvastatin 10 mg/day on mild coronary atherosclerotic plaques.                 2012         143/128          Stable angina               56/53                       -47/-49                                  Ato 20 vs Ros 10                              6                                                       Usual doses of Ato and Ros induced significant regression of coronary atherosclerosis in statin-naive patients.

Abbreviations: RCT, randomized controlled trials; T, treatment group; C, control group IVUS, Intravascular ultrasound; CAD, Coronary artery disease; ACS, Acute coronary syndrome; CHD, Coronary heart disease; Ato, Atorvastatin; Ros, Rosuvastatin; Pra, Pravastatin; Pit, Pitavastatin; Sim, Simvastatin; Flu, Fluvastatin; Con, Control; Pac, Pactimibe; Tor, Torcetrapib, Ava 50, 250, 750, Avasimibe 50, 250, 750 mg; T/C, Treat/Control; Gli, Glimepiride; Pio, Pioglitazone; Rim, Rimonabant.

###### 

The levels of LDL-C at baseline and follow up in each arm of included trials

   **Authors**   **Trial name**   **Management in each arm**   **N**   **LDL-C level**  
  ------------- ---------------- ---------------------------- ------- ----------------- ----------------
    Tardif JC        A-PLUS              Avasimibe50            108      92.8 ± 1.7          100\*
    Tardif JC        A-PLUS              Avasimibe250           98       93.4 ± 1.6         101.9\*
    Tardif JC        A-PLUS              Avasimibe750           117      91.4 ± 1.6         101.4\*
    Tardif JC        A-PLUS                Placebo              109      89.6 ± 1.6          91.1\*
    Okazaki S      ESTABLISH               Control              24      123.9 ± 35.3      119.4 ± 24.6
    Okazaki S      ESTABLISH             Atorvastatin           24      124.6 ± 34.5      70.0 ± 25.0
   Yokoyama M                              Control              30      131.5 ± 23\#     124.5 ± 24.1\#
   Yokoyama M                            Atorvastatin           29        133 ± 13          87 ± 29
    Nissen SE       REVERSAL             Atorvastatin           253     150.2 ± 27.9      78.9 ± 30.2
    Nissen SE       REVERSAL             Pravastatin            249     150.2 ± 25.9      110.4 ± 25.8
    Nissen SE       ACTIVATE              Pactimibe             206     101.4 ± 27.7          91.3
    Nissen SE       ACTIVATE               Placebo              202     101.5 ± 31.1          86.4
    Nissen SE      ILLUSTRATE            Atorvastatin           446      84.3 ± 18.9      87.2 ± 22.6
    Nissen SE      ILLUSTRATE         Atorva+torcetrapib        464      83.1 ± 19.7      70.1 ± 25.4
   Kawasaki M                              Control              17        152 ± 20          149 ± 24
   Kawasaki M                            Pravastatin            18        149 ± 19          102 ± 13
   Kawasaki M                            Atorvastatin           17        155 ± 22          95 ± 15
     Hiro T        JAPAN-ACS             Pitavastatin           125     130.9 ± 33.3      81.1 ± 23.4
     Hiro T        JAPAN-ACS             Atorvastatin           127     133.8 ± 31.4      84.1 ± 27.4
    Nissen SE       ASTEROID             Rosuvastatin           349     130.4 ± 34.3      60.8 ± 20.0
   Takayama T        COSMOS              Rosuvastatin           126      140.2±31.5        82.9±18.7
     Lee CW          ARTMAP              Atorvastatin           143       110 ± 31          56 ± 18
     Lee CW          ARTMAP              Rosuvastatin           128       109 ± 31           53±18
    Yamada T         REACH               Atorvastatin           26        123 ± 17          83 ± 22
    Yamada T         REACH                 Control              32        115 ± 14          115 ± 30
     Nasu K                              Fluvastatin            40      144.9 ± 31.5      98.1 ± 12.7
     Nasu K                                Control              39      122.3 ± 18.9      121.0 ± 21.2
   Nicholls SJ       SATURN              Atorvastatin           519     119.9 ± 28.9       70.2 ± 1.0
   Nicholls SJ       SATURN              Rosuvastatin           520     120.0 ± 27.3       62.6 ± 1.0
     Hong MK                             Simvastatin            50        119 ± 30          78 ± 20
     Hong MK                             Rosuvastatin           50        116 ± 28          64 ± 21
     Tani S                              Pravastatin            52        130 ± 38          104 ± 20
     Tani S                                Control              23        123 ± 28          120 ± 30
   Rodés-C Bef       ERASE            Statins before ACS        38         71 ± 23          77 ± 25
   Rodés-C Aft       ERASE            Statins after ACS         36        100 ± 30          63 ± 17
    Jensen LO                            Simvastatin            40      158.7 ± 30.6      85.1 ± 22.1
    Nissen SE      PERISCOPE             Statins+Gli            181      94.4 ± 32.9      96.1 ± 30.4
    Nissen SE      PERISCOPE             Statins+Pio            179      93.5 ± 30.7      95.6 ± 28.9
    Nissen SE     STRADIVARIUS           Statins+Rim            335      91.9 ± 27.9      87.6 ± 30.5
    Nissen SE     STRADIVARIUS           Statins+Con            341      89.5 ± 32.2      86.3 ± 30.3

Note: \*calculated on the bases of baseline levels and change percentage at follow up \[[@B21]\].

\# calculated according to Figure [2](#F2){ref-type="fig"} in the paper \[[@B15]\].

Risk of bias of included studies, evaluated through Cochrane's methods, showed an overall acceptable quality of selected trials (Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}).

![Methodological quality summary of each included trial.](1471-2261-14-60-2){#F2}

![Methodological quality graph: each methodological quality item presented as percentages across all included studies.](1471-2261-14-60-3){#F3}

The effect of the levels of LDL-C at follow-up on regression of coronary atherosclerotic plaque
-----------------------------------------------------------------------------------------------

LDL-C lowering in group ≤70 and \>70 ≤ 100HP mg/dL could lead to regression of CAP, but LDL-C lowering in group \>70 ≤ 100MP, \>70 ≤ 100LP and \>100 mg/dL could not (Figure [4](#F4){ref-type="fig"}, Table [3](#T3){ref-type="table"}).

![**Meta-analysis of the effects of reduction levels of LDL-C at follow up on the regression of coronary atherosclerotic plaque.** Abbreviations: Ato, Atorvastatin; Ros, Rosuvastatin; Pra, Pravastatin; Pit, Pitavastatin; Sim, Simvastatin; Flu, Fluvastatin; Con, Control; Pac, Pactimibe; Tor, Torcetrapib, Ava 50, 250, 750, Avasimibe 50, 250, 750 mg; Bef, before ACS; Aft, after ACS; Gli, Glimepiride; Pio, Pioglitazone; Rim, Rimonabant.](1471-2261-14-60-4){#F4}

###### 

Results of meta-analysis in each group and mean CAP volume in each group at baseline and follow up

                **Group**              **Included arms (case)**      **CAP Volume at Baseline (mm**^**3**^**)**   **CAP Volume at Follow up (mm**^**3**^**)**     **Pooled SMD (95% CI,*p*)**     **Heterogeneity test**   **Sensitivity analyses**       **Egger's test**                                 
  --------------------------------- ------------------------------- -------------------------------------------- --------------------------------------------- --------------------------------- ------------------------ -------------------------- -------------------------- -------------------------- -------
               ≤70 mg                          7 (1250)                              177.1±41.9                                   125.9±38.6                    -0.156 (-0.235\~ -0.078, 0.000)        0.57 (0.997)                   0               -0.146 (-0.238\~ -0.054)   -0.167 (-0.270\~ -0.064)   0.835
      Without 2006 ASTEROID Ros         Without 2011 SATURN Ros                                                                                                                                                                                                                                            
            \>70≤100HP mg                      11 (1352)                             129.7±72.3                                   123.8±69.8                    -0.123 (-0.199\~ -0.048, 0.001)        6.83 (0.741)                   0               -0.103 (-0.182\~ -0.024)   -0.151 (-0.235\~ -0.067)   0.501
     Without 2009 JAPAN-ACS Ato        Without 2004 REVERSAL Ato                                                                                                                                                                                                                                           
            \>70≤100MP mg                      5 (1548)                              195.8±2.3                                     191.8±4.7                    -0.045 (-0.115\~ -0.026, 0.215)        1.59 (0.811)                   0               -0.016 (-0.103\~ -0.066)   -0.061 (-0.140\~ -0.019)   0.500
   Without 2007 ILLUSTRATE Ato+Tor   Without 2008 STRADIVARIUS Con                                                                                                                                                                                                                                         
            \>70≤100LP mg                      6 (1061)                              201.2±15.1                                   197.3±15.0                     -0.045 (-0.130\~0.040, 0.301)         1.14 (0.950)                   0               -0.024 (-0.136\~ 0.087)    -0.059 (-0.148\~ 0.031)    0.241
     Without 2007 ILLUSTRATE Ato      Without 2004 A-PLUS Ava 50                                                                                                                                                                                                                                           
              \>100 mg                         10 (669)                              175.9±86.4                                   178.7±89.1                     0.017 (-0.090\~0.124, 0.757)          2.37 (0.984)                   0               -0.000 (-0.135\~ 0.136)     0.039 (-0.073\~ 0.151)    0.692
      Without 2004 REVERSAL Pro         Without 2005 Tani S Pra                                                                                                                                                                                                                                            
                \<0%                           8 (1276)                              201.2±13.8                                   198.3±13.8                    -0.034 (-0.111\~ 0.044, 0.396)         1.55 (0.981)                   0               -0.012 (-0.109\~ 0.084)    -0.044 (-0.125\~ 0.037)    0.087
     Without 2007 ILLUSTRATE Ato      Without 2004 A-PLUS Ava 50                                                                                                                                                                                                                                           
               \>0≤30%                         13 (2014)                             188.6±51.7                                   186.3±52.7                    -0.032 (-0.093\~ 0.030, 0.315)         4.59 (0.970)                   0               -0.010 (-0.080\~ 0.061)    -0.042 (-0.108\~ 0.024)    0.537
   Without 2007 ILLUSTRATE Ato+Tor     Without 2004 REVERSAL Pra                                                                                                                                                                                                                                           
              \>30≤40%                         10 (594)                              102.9±96.9                                    94.3±90.4                    -0.199 (-0.314\~ -0.085, 0.001)        3.10 (0.960)                   0               -0.166 (-0.295\~ -0.038)   -0.214 (-0.342\~ -0.085)   0.024
     Without 2009 JAPAN-ACS Ato         Without 2009 COSMOS Ros                                                                                                                                                                                                                                            
              \>40≤50%                         8 (1677)                              157.8±37.8                                   150.7±36.3                    -0.108 (-0.176\~ -0.040, 0.002)        2.50 (0.927)                   0               -0.093 (-0.174\~ -0.011)   -0.126 (-0.200\~ -0.053)   0.605
       Without 2011 SATURN Ros         Without 2004 REVERSAL Ato                                                                                                                                                                                                                                           
                \>50%                           1 (349)                              212.2±81.3                                   197.5±79.1                    -0.183 (-0.332\~ -0.035, 0.016)                                                                                                                

In group ≤70 mg/dL (including seven arms) with mean 18.6 months of follow up and group \>70 ≤ 100HP mg/dL (including eleven arms) with mean 17.4 months of follow up, the volumes of CAP (125.9, 123.8 mm^3^ respectively) at follow up were significantly decreased, compared with the volumes (177.1, 129.7 mm^3^ respectively) at baseline \[SMD −0.156 mm^3^, 95% CI (confidence interval) -0.235 \~ −0.078, *p* = 0.000; SMD −0.123 mm^3^, 95% CI −0.199 \~ −0.048, *p* = 0.001; respectively\]. There was no significant heterogeneity among arms (χ^*2*^ for heterogeneity = 0.57, *p* =0.997, *I*^2^ = 0% for group ≤70 mg/dL; χ^*2*^ for heterogeneity = 6.83, *p* =0.741, *I*^2^ = 0% for group \>70 ≤ 100HP mg/dL).

Sensitivity analyses suggested that LDL-C lowering in group ≤70 and \>70 ≤ 100HP mg/dL could lead to regression of CAP with reduction of the CAP volume ranged from −0.146 mm^3^ (SMD, 95% CI: −0.238 \~ −0.054) when the arm of 2006 ASTEROID Ros was omitted to −0.167 mm^3^ (SMD, 95% CI: −0.270 \~ −0.064) when the arm of 2011 SATURN Ros was omitted; and from −0.103 mm^3^ (SMD, 95% CI: −0.182 \~ −0.024) when the arm of 2009 JAPAN-ACS Ato was omitted to −0.151 mm^3^ (SMD, 95% CI: −0.235 \~ −0.067) when the arm of 2004 REVERSAL Ato was omitted. No publication bias was found, the values of *p* by Egger's test for group ≤70 and \>70 ≤ 100HP mg/dL were 0.835, 0.501 respectively.

In group \>100 mg/dL (including eleven arms) with mean 14.6 months of follow up, the volume of CAP at follow up was not significantly increased, compared with the volumes at baseline (SMD 0.013 mm^3^, 95% CI −0.092 \~ 0.118, *p* = 0.809). There was no significant heterogeneity among arms (χ^*2*^ for heterogeneity = 2.49, *p* =0.991, *I*^2^ = 0%).

Sensitivity analyses suggested that LDL-C lowering to \>100 mg/dL at follow-up could still not lead to regression of CAP with reduction of the plaque volume ranged from −0.005 mm^3^ (95% CI −0.136 \~ 0.126) when the arm of 2004 REVERSAL Pro was omitted to 0.034 mm^3^ (SMD, 95% CI −0.075 \~ 0.143) when 2005 Tani S Pra was omitted. No publication bias was observed from the values of *p* (0.566) by Egger's test.

Mean levels of LDL-C at baseline and follow up and mean reducing percentage of LDL-C in group ≤70, \>70 ≤ 100HP, \>70 ≤ 100MP, \>70 ≤ 100LP and \>100 mg/dL were showed in Table [4](#T4){ref-type="table"}.

###### 

Levels and reducing percentage of LDL-C and duration in each group

     **Group**     **N**   **Mean LDL-C at Baseline (mg)**   **Mean LDL-C at Follow up (mg)**   **Mean Reducing percentage**   **Actual range of reducing percentage**   **Duration (month)**
  --------------- ------- --------------------------------- ---------------------------------- ------------------------------ ----------------------------------------- ----------------------
      ≤70 mg       1250               120.0±8.2                          60.6±3.5                         48.8±3.3                            37\~53.2                         18.6±8.2
   \>70≤100HP mg   1352              132.4±12.9                          77.8±7.0                         40.4±4.0                           32.3\~46.7                        17.4±5.9
   \>70≤100MP mg   1548               91.3±6.9                           82.4±8.2                         9.1±4.5                             3.6\~14.9                        19.8±2.7
   \>70≤100LP mg   1061               88.5±5.5                           91.5±5.4                         -4.7±2.5                           -1.7\~-8.5                        19.9±4.5
     \>100 mg       699              125.1±24.4                         110.0±9.3                         8.3±15.6                            -10.9\~32                        14.6±5.1
       \<0%        1276               89.1±5.3                           93.2±6.2                         -5.6±3.1                           -1.7\~-10.9                       19.6±4.2
      \>0≤30%      2014              102.4±22.1                         89.7±15.7                         10.6±7.3                              0\~25                          18.3±4.5
     \>30≤40%       594              132.6±11.4                          83.3±7.7                         36.1±1.9                             32\~39                          10.3±3.1
     \>40≤50%      1677              123.7±13.4                          66.8±8.0                         45.4±2.8                            41.5\~49                         19.4±6.9
       \>50%        349              130.4±34.3                         60.8±20.0                           53.2                                53.2                              24

The effect of the LDL-C reducing percentage at follow-up on regression of CAP
-----------------------------------------------------------------------------

LDL-C lowering in group ≥30 \< 40, ≥40 \< 50, ≥50% could lead to regression of CAP, but LDL-C lowering in group \<0 and ≥0 \< 30% could not (Figure [5](#F5){ref-type="fig"}, Table [3](#T3){ref-type="table"}).

![**Meta-analysis of the effects of reduction percentages of LDL-C at follow up on the regression of coronary atherosclerotic plaque.** Abbreviations: Ato, Atorvastatin; Ros, Rosuvastatin; Pra, Pravastatin; Pit, Pitavastatin; Sim, Simvastatin; Flu, Fluvastatin; Con, Control; Pac, Pactimibe; Tor, Torcetrapib, Ava 50, 250, 750, Avasimibe 50, 250, 750 mg; Bef, before ACS; Aft, after ACS; Gli, Glimepiride; Pio, Pioglitazone; Rim, Rimonabant.](1471-2261-14-60-5){#F5}

In group ≥30 \< 40% (including ten arms) with mean 10.3 months of follow up, and group ≥40 \< 50% (including eight arms) with mean 19.4 months of follow up, the volumes of CAP (94.3, 150.7 mm^3^ respectively) at follow up were significantly decreased, compared with the volumes (102.9, 157.8 mm^3^ respectively) at baseline (SMD −0.199 mm^3^, 95% CI −0.314 \~ −0.085, *p* = 0.001; SMD −0.108 mm^3^, 95% CI −0.176 \~ −0.040, *p* = 0.002; respectively). There was no significant heterogeneity among arms (χ^*2*^ for heterogeneity = 3.10, *P* = 0.960, *I*^2^ = 0%; χ^*2*^ for heterogeneity = 2.50, *p* =0.927, *I*^2^ = 0%; for group ≥30 \< 40, and group ≥40 \< 50 respectively).

Sensitivity analyses showed that LDL-C lowering in group ≥30 \< 40% and group ≥40 \< 50 could still lead to regression of CAP with reduction of the plaque volume ranged from −0.166 mm^3^ (95% CI −0.295 \~ −0.038) when the arm of 2009 JAPAN-ACS Ato was omitted to −0.214 mm^3^ (SMD, 95% CI −0.342 \~ −0.085) when 2009 COSMOS Ros was omitted; from −0.093 mm^3^ (95% CI −0.174 \~ −0.011) when the arm of 2011 SATURN Ros was omitted to −0.126 mm^3^ (SMD, 95% CI −0.200 \~ −0.053) when 2004 REVERSAL Ato was omitted respectively. Publication bias analysis suggested the values of *p* by Egger's test were 0.024, 0.605 for group ≥30 \< 40, and group ≥40 \< 50 respectively.

In group \<0 with mean 19.6 months of follow up and group ≥0 \< 30% with mean 18.3 months of follow up, the volume of CAP at follow up was not significantly decreased, compared with the volumes at baseline (SMD −0.034 mm^3^, 95% CI −0.111 \~ 0.044, *p* = 0.396; SMD −0.032 mm^3^, 95% CI −0.093 \~ 0.030, *p* = 0.315 respectively). There was no significant heterogeneity among arms (χ^*2*^ for heterogeneity = 1.55, *p* =0.981, *I*^2^ = 0% for group \<0%; χ^*2*^ for heterogeneity = 4.59, *p* =0.970, *I*^2^ = 0% for group ≥0 \< 30%).

Sensitivity analyses showed that LDL-C lowering in group ≥0 \< 30% could not still significantly decrease the volume of CAP with reduction of the CAP volume ranged from −0.010 mm^3^ (SMD, 95% CI: −0.080 \~ 0.061) when the arm of 2007 ILLUSTRATE Ato + Tor was omitted to −0.042 mm^3^ (SMD, 95% CI: −0.108 \~ 0.024) when the arm of 2004 REVERSAL Pro was omitted. No publication bias was found, the values of *p* by Egger's test for group ≥0 \< 30% were 0.537.

Mean levels of LDL-C at baseline and follow up, mean reducing percentage of LDL-C in group \<0, ≥0 \< 30, ≥30 \< 40, ≥40 \< 50 and ≥50%, were showed in Table [4](#T4){ref-type="table"}.

The effect of lowering LDL-C by statins on regression of coronary atherosclerotic plaque
----------------------------------------------------------------------------------------

LDL-C lowering by rosuvastatin, atorvastatin and pitavastatin in group ≤70 and \>70 ≤ 100HP mg/dL could lead to regression of CAP, but LDL-C lowering by simvastatin, fluvastatin and pravastatin could not (Figure [6](#F6){ref-type="fig"}, Table [5](#T5){ref-type="table"}).

![**Meta-analysis of the effects of LDL-C lowering by different statins on the regression of coronary atherosclerotic plaque.** Abbreviations: Ato, Atorvastatin; Ros, Rosuvastatin; Pra, Pravastatin; Pit, Pitavastatin; Sim, Simvastatin; Flu, Fluvastatin; Con, Control; Pac, Pactimibe; Tor, Torcetrapib, Ava 50, 250, 750, Avasimibe 50, 250, 750 mg; Bef, before ACS; Aft, after ACS; Gli, Glimepiride; Pio, Pioglitazone; Rim, Rimonabant.](1471-2261-14-60-6){#F6}

###### 

Results of meta-analysis in different statins groups

             **Group**           **Included arms (and case)**     **Pooled SMD (95% CI,*p*)**     **Heterogeneity test**   **Sensitivity analyses**      **Egger's test**                                
  ----------------------------- ------------------------------ --------------------------------- ------------------------ -------------------------- ------------------------- ------------------------- -------
          Rosuvastatin                     5 (1173)             -0.162 (-0.234\~ -0.081, 0.000)        0.37 (0.985)                   0               -0.153 (-0.249\~-0.056)   -0.178 (-0.287\~-0.069)   0.770
    Without 2006 ASTEROID Ros      Without 2011 SATURN Ros                                                                                                                                               
          Atorvastatin                     8 (1138)             -0.101 (-0.184\~ -0.019, 0.016)        4.44 (0.728)                   0               -0.075 (-0.162\~0.012)    -0.132 (-0.225\~-0.038)   0.582
   Without 2009 JAPAN-ACS Ato     Without 2004 REVERSAL Ato                                                                                                                                              
          Pitavastatin                     1 (125)              -0.304 (-0.553\~-0.055, 0.017)                                                                                                               
           Fluvastatin                      1 (40)               -0.169 (-0.608\~0.270, 0.450)                                                                                                               
           Simvastatin                      2 (90)               -0.10 (-0.393\~ 0.192, 0.501)         0.04 (0.846)                   0               -0.074 (-0.467\~0.318)    -0.133 (-0.572\~0.360)    0.000
   Without 2004 Jensen LO Sim      Without 2009 Hong MK Sim                                                                                                                                              
           Pravastatin                     3 (319)               -0.008 (-0.163\~0.147, 0.920)         1.86 (0.395)                   0               -0.005 (-0.165\~0.154)     0.039 (-0.131\~0.208)    0.528
   Without 2005 Kawasaki M Pra     Without 2005 Tani S Pra                                                                                                                                               

LDL-C lowering by rosuvastatin (mean 33.3 mg daily for mean 20 months), atorvastatin (mean 60.3 mg daily for mean 17 months) and pitavastatin (4 mg daily for 8 \~ 12 months) in group ≤70 and \>70 ≤ 100HP mg/dL could significantly decrease the volumes of CAP at follow up, compared with the volumes at baseline (SMD −0.162 mm^3^, 95% CI: −0.234 \~ −0.081, *p* = 0.000; SMD −0.101, 95% CI: −0.184 \~ −0.019, *p* = 0.016; SMD −0.304 mm^3^, 95% CI: −0.553 \~ −0.055, *p* = 0.017; respectively). There was no significant heterogeneity among arms (χ^*2*^ for heterogeneity = 0.37, *p* =0.985, *I*^2^ = 0% for rosuvastatin; χ^*2*^ for heterogeneity = 4.44, *p* =0.728, *I*^2^ = 0% for atorvastatin.

Sensitivity analyses suggested that lowering LDL-C by rosuvastatin could lead to regression of CAP with reduction of the plaque volume ranged from −0.153 mm^3^ (SMD, 95% CI: −0.249 \~ −0.056) when the arm of 2006 ASTEROID Ros was omitted to −0.178 mm^3^ (SMD, 95% CI: −0.287 \~ −0.069) when the arm of 2011 SATURN Ros was omitted. Lowering LDL-C by atorvastatin could, but not significantly, lead to regression of CAP when the arm of 2009 JAPAN-ACS Ato was omitted (SMD: −0.075 mm^3^, 95% CI: −0.162 \~ 0.012). No publication bias was found, the values of *p* by Egger's test for rosuvastatin and atorvastatin group were 0.770, 0.582 respectively (Table [5](#T5){ref-type="table"}).

Intensity of lowering LDL-C by different statins was shown in Table [6](#T6){ref-type="table"}. Rosuvastatin and atorvastatin could reduce LDL-C by more than 40%.

###### 

Levels and reducing percentage of LDL-C, dosage and duration in different statin group

    **Group**     **N**    **Age**    **MeanLDL-C at Baseline (mg)**   **MeanLDL-C at Follow up (mg)**   **Mean Reducing percentage**   **Statin dosage (mg)**   **Duration (month)**
  -------------- ------- ----------- -------------------------------- --------------------------------- ------------------------------ ------------------------ ----------------------
   Rosuvastatin   1173    58.1±1.8              123.9±8.6                         63.3±7.4                         48.4±4.2                   33.3±11.6                20.5±6.3
   Atorvastatin   1138    58.4±2.5              128.0±14.0                        73.0±8.7                         42.3±3.7                   60.3±28.6                17.5±7.1
   Pitavastatin    125    62.5±11.5             130.9±33.3                        81.1±23.4                       36.2±19.5                       4                     8\~12
   Fluvastatin     40     63.0±10.0             144.9±31.5                        98.1±12.7                          32.3                         60                      12
   Simvastatin     90     57.9±0.1              136.61±5.3                        81.2±3.5                         39.9±6.1                   28.9±10.0                17.8±6.5
   Pravastatin     319    58.2±3.2              146.8±7.4                         108.9±2.9                        24.6±2.6                    34.8±9.9                15.4±5.0

Discussion
==========

Feature of this meta-analysis
-----------------------------

This meta-analysis broke though the limit of single trial, and pooled arms together according to the levels of LDL-C at follow up in the arms, regardless of the measures of lowering LDL-C: treating arm (statins, ACAT inhibitor, CETP inhibitor, decreasing obesity drug, and glucose-lowering agents) and control arms (dietary restriction, moderate LDL-C lowering by statin); intensive and moderate LDL-C lowering. The volumes of CAP at follow up were compared with those at baseline in the same arms to evaluate the regression of the CAPs, this meta-analysis really reflected the change of the plaques volume with the change of LDL-C levels.

Our meta-analysis results indicated that intensive lowering LDL-C in group ≤70, \>70 ≤ 100HP mg/dL (mean follow up LDL-C, mean duration of follow up: 60.6 mg/dL, 18.6 months; 77.8 mg/ dL, 17.4 months respectively), ≥30 \< 40, ≥40 \< 50 and ≥50% (mean LDL-C reducing, mean duration of follow up: 36.1%, 10.3 months; 45.4%, 19.4 months; 53.2%, 24 months respectively) could lead to the regression of CAP; that moderate lowering LDL-C in group \>70 ≤ 100MP mg/dL (mean LDL-C reducing by 9.1%, mean 19.8 months of follow up), \>100 (mean follow up LDL-C 110.0 and mean 14.6 months of follow up) mg/dL and ≥0 \< 30% (mean LDL-C reducing by 10.6%, mean 18.3 months of follow up) could not lead to the regression; and that intensive lowering LDL-C, by mean 48% with rosuvastatin, and by mean 42% with atorvastatin, could regress CAP. The sensitivity analysis confirmed the effect of the LDL-C change on the volume of the plaque.

The importance of intensive lowing LDL-C on regression of CAP and LDL-C target of this meta-analysis
----------------------------------------------------------------------------------------------------

In the trials that evaluated the effects of LDL-C lowering on atheroma progression by IVUS, the effects varied with level of LDL-C at follow up. In group ≤70 mg, ≥30 \< 40% and ≥40 \< 50%, the LDL-C at baseline in most trials (including ESTABLISH \[[@B14]\], REVERSAL \[[@B13]\], JAPAN-ACS \[[@B12]\], ASTEROID \[[@B37]\], COSMOS \[[@B40]\], trial by Kawasaki M \[[@B16]\] and by Nasu K \[[@B41]\]) were \>120 mg. In ASTEROID \[[@B37]\], COSMOS \[[@B40]\], JAPAN-ACS \[[@B12]\] trial and fluvastatin arm of the trial by Nasu K \[[@B41]\] with respective the mean LDL-C level 60.8 mg, 82.9 mg, 81-84 mg and 98 mg (53.2%, 38.6%, 36% and 32.3% reduction of level of LDL-C) at follow up, it was showed that CAP could be regressed with intensive statin therapy. In ESTABLISH \[[@B14]\] and REVERSAL \[[@B13]\], the mean reducing percent of LDL-C at follow up in the statin treatment arms were 44% and 46% respectively, the volumes of CAPs at follow up were not significantly decreased, compared with those in baseline. In the trails by Yokoyama M \[[@B15]\] and Kawasaki M \[[@B16]\], mean reducing percentage of LDL-C at follow up was 35% for atorvastatin arm of the trial by Yokoyama M \[[@B15]\], 32% for pravastatin arm of the trial by Kawasaki M \[[@B16]\] and 39% for atorvastatin arm of the trial by Kawasaki M \[[@B16]\], the volume of CAPs at follow up were also not significantly decreased, compared with that at baseline. Pooled these arms with follow up LDL-C ≤70 mg or reducing \>30% together, these meta-analysis showed that the CAPs could be regressed in group ≤70 mg, ≥30 \< 40% and ≥40 \< 50%. Because of publication bias in group ≥30 \< 40% (Table [3](#T3){ref-type="table"}), the level of LDL-C in this group could not be recommended for regressing CAP. Based on the mean level and reducing percentage of LDL-C in group ≤70 mg and ≥40 \< 50% (60.6 ± 3.5 mg, 48.8 ± 3.3%; 66.8 ± 8.0 mg, 45.4 ± 2.8%, in Table [4](#T4){ref-type="table"}), the meta-analysis in group ≤70 mg and ≥40 \< 50% suggested that for regressing CAP, LDL-C should be reduced by \>45% or to a target level ≤ 66 mg/dL.

In trials with 18--24 months of non-statin (ACAT inhibitor, decreasing obesity drugs and glucose-lowering agents) treatment, although the levels of LDL-C at follow up in some arms (ACTIVATE \[[@B22]\], STRADIVARIUS \[[@B35]\], PERISCOPE \[[@B36]\], and A-PLUS \[[@B21]\] with daily 50 mg of avasimibe) were \>70 ≤ 100 mg/dL, the LDL-C lowering percentage at follow up in the arms were below 30% because the levels of LDL-C at baseline were \<95 mg/dL. In ILLUSTRATE trial \[[@B23]\], after treatment with atorvastatin to reduce levels of LDL-C to less than 100 mg/dL, patients were randomly assigned to receive either atorvastatin monotherapy or atorvastatin plus 60 mg of torcetrapib daily. After 24 months, the reduction of LDL-C in both arms was \<24% and the progression of CAP was not halted. In trial \[[@B34],[@B35]\] with statins treatment and baseline LDL-C \< 110 mg, if the LDL-C lowering percentage at follow up were \<24%, the CAP was also not regressed. The meta analysis with six arms in group \>70 ≤ 100LP mg/dL and five arms in group \>70 ≤ 100MP mg/dL did not show that only \>70 ≤ 100 mg/dL of LDL-C level but \<30% reduction at follow up could lead to regression of CAP, which further confirmed the importance of intensively lowering LDL-C in regression of CAP. Though LDL-C at follow up in some trials \[[@B13],[@B15],[@B16],[@B26],[@B27],[@B39]\] of LDL-C lowering by statins was \>70 ≤ 100 mg/dL and reducing \>30%, the CAP in the trials was also not regressed. Included eleven arms with baseline LDL-C \>130.0 mg/dL, follow up LDL-C \>70 ≤ 100 mg/dL and LDL-C reducing \>30% (in group \>70 ≤ 100HP mg), this meta-analysis suggested that LDL-C reducing \>40% or to target 77.8 mg could regress CAP (Table [4](#T4){ref-type="table"}). The meta-analysis in group \>70 ≤ 100HP, \>70 ≤ 100MP and \>70 ≤ 100LP mg/dL indicated that LDL-C reducing percentage, not lowering absolute value of LDL-C at follow up, was important for regressing CAP.

Although rosuvastatin, atorvastatin, pitavastatin, simvastatin, and fluvastatin in some trials could reduce LDL-C level to ≤100 mg or by 30%, the meta-analysis indicated that rosuvastatin, atorvastatin and pitavastatin (mean lowering LDL-C by 48.4%, 42.3% and 36.2% respectively) could regress the CAPs, and simvastatin with mean lowering LDL-C by 39.9% could not. The role of pitavastatin in regressing CAPs remains to be verified because the role was from only one RCT with 125 cases \[[@B12]\]. Pravastatin with mean lowering LDL-C by 24.6% could not regress the CAPs either. Fluvastatin with mean lowering LDL-C by 32.3% in the blinded endpoint trial with 40 patients can regress the CAP \[[@B41]\], but meta-analysis indicated that fluvastatin could not regress the CAP. The reason that pravastatin and fluvastatin in this meta--analysis can not regress the CAPs might be attributed to their low-intensity of lowering LDL-C and low dosage which can not reduce LDL-C by \>40%.

Taken all the results of meta-analysis together, it was recommended that LDL-C level should be reduced by \>40% or to a target level \< 78 mg/dL for regressing CAP.

The difference of LDL-C target level between this meta-analysis and current guidelines
--------------------------------------------------------------------------------------

The patients included in this meta-analysis were coronary heart disease. According to 2004 the guideline of the Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program \[[@B43]\] and 2011 ESC/EAS Guidelines for the management of dyslipidaemias \[[@B1]\], this group of patients belongs to very high risk category, and the recommended targets of LDL-C should be less than 70 mg/dL or 30-40% reduction from baseline in ATP III, and less than 70 mg/dL or a ≥50% reduction in 2011 ESC/EAS Guidelines. The target levels for subjects at very high risk in the both guidelines are extrapolated from several clinical trials \[[@B43]\], mainly from the meta-analysis by Cholesterol Treatment Trialists' Collaborators \[[@B44]\], which indicated that absolute benefit of LDL-C lowering related chiefly to the absolute reduction of LDL-C, and the risk reductions are proportional to the absolute LDL-C reductions, but the meta-analysis did not provide target level of LDL-C for the benefit in terms of cardiovascular disease reduction \[[@B44]\]. According to 2013 ACC/AHA blood cholesterol guideline \[[@B45]\], this group of patients should be treated with high-intensity statin (atorvastatin 40--80 mg daily or rosuvastatin 20--40 mg daily), which was the intensity of statin suggested in this meta-analysis (Table [6](#T6){ref-type="table"}).

The results of our meta-analysis imply that the patients with CHD should be intensively treated with statins (rosuvastatin 33 mg or atorvastatin 60 mg daily) to reduce the level of LDL-C by \>40% or to a target level \<78 mg/dL for regressing CAP, which have a little different to the guidelines. These different targets level of LDL-C might be due to different observational index: cardiovascular events for both guidelines, CAP volume for this meta-analysis. Moreover, our target is directly from meta-analysis, the target of 2011 ESC/EAS Guidelines is from extrapolation of meta-analysis, not a direct data. Our meta-analysis revealed the relation between the regression of coronary artery disease and LDL-C level from the view of pathological anatomy. Published meta-analysis \[[@B17],[@B18]\] about CAP by IVUS did not review the relationship between LDL-C level and CAP.

Study limitation
----------------

The results of this analysis were obtained by pooling data from twenty clinical trials. As with any meta-analysis, this study has some limitations. Firstly, though no publication bias was observed by Egger's test there may be a potential of publication bias because only published data were included. Secondly, the methodology used for measurement of coronary atheroma might not be the same in the studies. The plaques volume may be calculated from slices with 1 mm apart for a length of 10 mm vessel in some trials \[[@B13],[@B15],[@B22],[@B23],[@B27]-[@B29],[@B37]\], or 0.1-0.3 mm-apart for a length of 10--50 mm vessel in other trials \[[@B12],[@B21],[@B33],[@B39],[@B40]\], which might affect accuracy of plaque measurement. There were some differences in selecting plaque: some trials assessed the plaque in non-culprit vessel, while others assessed non-culprit plaque in a culprit vessel \[[@B12],[@B14],[@B34]\], which assured the plaque was stable. Our study focus on target plaque change, i.e. plaque regression or progression, those differences in measurements and plaque selection did not affect the change of the target plaque with LDL-C levels. So, it has little effect on homogeneous of studies, and this detection bias was very much limited from values of *P* in χ^*2*^ test and *I*^2^ in each group. Thirdly, follow up duration might have some effects of the changes of CAP. Fourthly, other cardiovascular risk factors but LDL-C levels, for example, demographic characteristics such as age, gender and ethnicity, might also affect the effect of LDL-C on CAP, and the effects of these factors on CAP remain to be investigated in future.

Implication for practice
------------------------

This meta-analysis investigated the effect of reduction of LDL-C only on the regression of the plaque, not on reduction of cardiovascular events. In fact, all the included trial have no the data about death because only the alive have IVUS data at follow up. But in four-year of the OLIVUS-Ex \[[@B46]\], it was found that patients with annual atheroma progression had more adverse cardio- and cerebrovascular events than the rest of the population. A meta-analysis \[[@B47]\] included 7864 CAD patients showed that rates of plaque volume regression were significantly associated with the incidence of MI or revascularization, and it was concluded that regression of atherosclerotic coronary plaque volume in stable CAD patients may represent a surrogate for myocardial infarction and repeat revascularization. Plaque in CAD, as blood pressure level in hypertension, is not major adverse cardiac events, but does be an important surrogate. Therefore, the conclusion of this meta-analysis not only applies to guide LDL-C lowering therapy for regressing CAP, may also apply to guide LDL-C lowering therapy for reducing major adverse cardio- and cerebrovascular events. Furthermore, high level of LDL-C plays a crucial role in the formation of atherosclerotic plaque, but LDL-C level is not unique risk factor for atherosclerotic plaque. Hypertension is another important risk factor for the formation of plaque \[[@B48],[@B49]\]. Smoking cessation, administrating β-blockers, anti-hypertension therapy might play some role in slowing progression of CAP \[[@B48],[@B50]-[@B52]\]. The trend of CAP regression in group \<0% might attribute to these non-LDL-C reducing factors.

Conclusions
===========

Atherosclerotic plaque extension and disruption are basic mechanism of atherosclerotic cardio- and cerebrovascular disease. Stabling and regressing atherosclerotic plaque play an important role in preventing cardio- and cerebrovascular disease. Pooled the twenty trials with CAP detected by gold standard: IVUS, this systemic review demonstrated that intensive lowering LDL-C (rosuvastatin mean 33 mg daily and atorvastatin mean 60 mg daily) with \>17 months of duration could lead to the regression of coronary atherosclerotic plaque, LDL-C level should be reduced by \>40% or to a target level \< 78 mg/dL for regressing CAP.
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